ALK-negative Anaplastic Large Cell Lymphoma: Clinical Trials

3 trials for ALK-negative Anaplastic Large Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 completed. 2 Phase 2, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Unknown 1
Phase 41Unknown 1

Follow ALK-negative Anaplastic Large Cell Lymphoma: new trials by email Literature Review of ALK-negative Anaplastic Large Cell Lymphoma trials Research Report on ALK-negative Anaplastic Large Cell Lymphoma

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms
Tislelizumab - Peripheral T Cell Lymphoma, PTCL
Phase 2CompletedBeiGene772018-04-132024-10-26
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
CEOP/IVE/GDP chemotherapy regimen, CEOP chemotherapy regimen for 6 cycles - Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T Cell Lymphoma
Phase 2UnknownShandong Provincial Hospital1062015-09-012020-03-10
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Cyclophosphamide 750mg/m2, Vincristine 1.4mg/m2, Doxorubicin 50mg/m2 - ALK-negative Anaplastic Large Cell Lymphoma, Peripherial T Cell Lymphoma,Not Otherwise Specified
Phase 4UnknownRuijin Hospital2002012-09-012017-11-14

Narrower conditions

Immunoblastic Lymphadenopathy (3)  ·  Enteropathy-Associated T-Cell Lymphoma (2)  ·  Lymphoma, T-Cell (2)  ·  Subcutaneous panniculitis-like T-cell lymphoma (2)  ·  Lymphoma, Extranodal NK-T-Cell (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, T-Cell, Cutaneous (1)  ·  Lymphoma, T-Cell, Peripheral (1)  ·  Recurrence (1)

Broader conditions

Hemic and Lymphatic Diseases (3)  ·  Immune System Diseases (3)  ·  Immunoproliferative Disorders (3)  ·  Lymphadenopathy (3)  ·  Lymphatic Diseases (3)  ·  Lymphoma (3)  ·  Lymphoma, Non-Hodgkin (3)  ·  Lymphoproliferative Disorders (3)  ·  Neoplasms (3)  ·  Neoplasms by Histologic Type (3)  ·  Disease Attributes (1)  ·  Lymphoma, T-Cell (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Cyclophosphamide (1)  ·  Doxorubicin (1)  ·  Etoposide (1)  ·  Ifosfamide (1)  ·  Methotrexate (1)  ·  Prednisone (1)  ·  Vincristine (1)  ·  etoposide phosphate (1)  ·  pirarubicin (1)  ·  prednylidene (1)  ·  tislelizumab (1)

Sponsors

BeiGene (1)  ·  Ruijin Hospital (1)  ·  Shandong Provincial Hospital (1)

Countries

China (3)  ·  Canada (1)  ·  France (1)  ·  Italy (1)  ·  Taiwan (1)

Top investigators

Xin Wang, PhD (1)

Results publications

PMID 32349779, PMID 37276067

NIH funding

2017 (1)